Raymond James Financial
KLRS

Raymond James Financial’s Kalaris Therapeutics KLRS Stock Holding History

Raymond James Financial’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$686K Buy
118,887
+30,451
+34% +$270K ﹤0.01% 4125
2025
Q4 		$746K Buy
+88,436
New +$565K ﹤0.01% 3980
2025
Q3 		– Sell
-2,629
Closed -$7.02K – 7008
2025
Q2 		$7.02K Buy
+2,629
New +$11.9K ﹤0.01% 6056
2025
Q1 		– Sell
-2,630
Closed -$25.4K – 4986
2024
Q4 		$25.4K Buy
+2,630
New +$39.8K ﹤0.01% 4697

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial's KLRS Position: Q1 2026 in Review

Raymond James Financial increased its Kalaris Therapeutics (KLRS) stake by 34% in Q1 2026, buying an estimated $270K and bringing the position to 118,887 shares worth $686K. The position accounts for ﹤0.01% of the portfolio, ranked #4125.

Raymond James Financial first reported a position in KLRS in Q4 2024 and has held it in 4 quarters since. The position peaked at $746K in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Raymond James Financial held 118,887 shares of Kalaris Therapeutics worth $686K as of Q1 2026.
  • Raymond James Financial bought 30,451 Kalaris Therapeutics shares in Q1 2026, an estimated $270K.
  • Kalaris Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4125 holding.
  • Raymond James Financial first reported a position in Kalaris Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Raymond James Financial's Kalaris Therapeutics position peaked at $746K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.